These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6141750)

  • 1. Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade.
    Cleophas TJ; van Lier HJ; Fennis JF; van 't Laar A
    Angiology; 1984 Jan; 35(1):29-37. PubMed ID: 6141750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha and beta-blockade and beta-stimulation in Raynaud's syndrome: a double-blind, placebo controlled, single dose study.
    Cleophas TJ; Fennis JF; van 't Laar A
    Angiology; 1985 Apr; 36(4):219-25. PubMed ID: 2862814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of alpha-adrenoceptor blockade in primary and secondary Raynaud's syndrome.
    Cleophas TJ; van Lier HJ; Faaber P; Fennis JF; van't Laar A
    Angiology; 1984 Nov; 35(11):719-23. PubMed ID: 6149709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.
    Wise RA; Wigley FM; White B; Leatherman G; Zhong J; Krasa H; Kambayashi J; Orlandi C; Czerwiec FS
    Arthritis Rheum; 2004 Dec; 50(12):3994-4001. PubMed ID: 15593189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.
    Hayoz D; Bizzini G; Noël B; Depairon M; Burnier M; Fauveau C; Rouillon A; Brouard R; Brunner HR
    Rheumatology (Oxford); 2000 Oct; 39(10):1132-8. PubMed ID: 11035135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.
    Csiki Z; Garai I; Shemirani AH; Papp G; Zsori KS; Andras C; Zeher M
    Microvasc Res; 2011 Jul; 82(1):84-7. PubMed ID: 21515290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension.
    Franssen C; Wollersheim H; de Haan A; Thien T
    J Clin Pharmacol; 1992 Jul; 32(7):652-9. PubMed ID: 1353506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raynaud's phenomenon caused by beta-receptor blocking drugs. Improvement after treatment with a combined alpha- and beta-blocker.
    Eliasson K; Danielson M; Hylander B; Lindblad LE
    Acta Med Scand; 1984; 215(4):333-9. PubMed ID: 6145298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.
    Wollersheim H; Thien T
    J Clin Pharmacol; 1988 Dec; 28(12):1089-93. PubMed ID: 3243924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of alpha and beta blockade on ventilatory responses to exercise in chronic heart failure.
    Witte KK; Thackray SD; Nikitin NP; Cleland JG; Clark AL
    Heart; 2003 Oct; 89(10):1169-73. PubMed ID: 12975409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up.
    Le Quentrec P; Lefebvre ML
    Angiology; 1991 Apr; 42(4):289-95. PubMed ID: 1673051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers: a new therapeutic approach to Raynaud's disease.
    Brotzu G; Susanna F; Roberto M; Palmina P
    Microvasc Res; 1987 Mar; 33(2):283-8. PubMed ID: 2884554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of ketanserin in hypertension and vasospastic disease.
    Wenting GJ; Brouwer RM; vd Meiracker AJ; Man in't Veld AJ; Schalekamp MA
    Acta Cardiol; 1987; 42(5):339-54. PubMed ID: 2827406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit.
    Surwit RS; Gilgor RS; Duvic M; Allen LM; Neal JA
    Arch Dermatol; 1983 Sep; 119(9):733-5. PubMed ID: 6614959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.